
VBL Therapeutics (NASDAQ:VBLT) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its drug candidate Ofra-Vec (VB-111) in combination with Paclitaxel for the treatment of patients with platinum-resistant ovarian cancer.
Ofra-vec is an investigational anti-cancer, gene-based agent from the company, in development to treat a wide range of solid tumors.